While metastatic patterns vary by subtype, NSCLC commonly spreads to the brain, bones, liver, and adrenal glands. Lymph node spread—especially mediastinal involvement—strongly influences staging and treatment selection. It is not possible to predict with certainty where metastasis will occur “first,” but symptoms (bone pain, neurologic changes, unexplained weight loss) and imaging findings guide evaluation. At diagnosis, PET-CT and, in selected scenarios, brain MRI are essential to define the full extent of disease. Once the spread map is clear, treatment typically combines systemic options (targeted therapy, immunotherapy, chemotherapy) and, when appropriate, local modalities (radiation/surgery) for control or symptom relief.